Synchron

15 articles with Synchron

• 

  Elon Musk’s Neuralink Beaten to the Clinic by Synchron

  5/13/2022

  Elon Musk’s Neuralink has been beaten to the clinic by rival brain-computer interface company Synchron which is assessing its implant in individuals with severe paralysis.

• Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

  5/4/2022

  Synchron today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patient in the US clinical trial, COMMAND, for patients with severe paralysis, at Mount Sinai Hospital in New York.

• 

  BioSpace Movers & Shakers, March 4

  3/4/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode™ Advances into Patients in US Clinical Trials

  2/22/2022

  Synchron to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth.

• NIH Backs Synchron Brain Computer Interface with $10M Grant to Launch First U.S. Clinical Trial

  8/26/2021

  NIH Backs Synchron Brain Computer Interface with $10M Grant to Launch First U.S. Clinical Trial

• Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US

  7/28/2021

  Synchron, a venture-backed brain data transfer company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application for its flagship product, the StentrodeTM motor neuroprosthesis.

• 

  Money on the Move: June 2-8

  6/9/2021

  Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week.

• Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface

  6/3/2021

  Synchron, a brain interface platform company , today announced that the company has secured $40M in a eries B round of financing led by Silicon Valley venture capital firm Khosla Ventures.

• Synchron’s Stentrode Brain-Computer Interface Receives Breakthrough Device Designation from FDA

  8/27/2020

  Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials

• Synchron Achieves First Successful Human Implantation of Brain Computer Interface

  9/20/2019

  Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive neural interface technology, a component of the Synchron Brain-Computer Interface.

• Synchron Initiates First-ever Clinical Trial to Evaluate Thought-to-Text™ Brain-Computer Interface Technology in Patients with Severe Paralysis

  4/8/2019

  Royal Melbourne Hospital study evaluates ability of minimally-invasive Stentrode™ neural interface technology in combination with BrainOS™ to restore communication in patients with severe paralysis due to stroke, motor neuron disease, ALS and spinal cord Injury

• Study Published in Nature Biomed Shows Promise for Patients with Neurological Conditions including Parkinson's disease, Depression and Epilepsy

  12/3/2018

  Synchron Inc., a company developing minimally invasive neural interface technology, today announced data demonstrating the feasibility of minimally-invasive techniques to enable focal brain stimulation has been published in the journal Nature Biomedical Engineering

• Synchron Secures $10 Million In Series A Financing Round

  4/4/2017

• Endovascular Start-up Synchron Appoints Neurovascular Veteran Martin Dieck as Chairman

  4/21/2016

• BioTrove, Inc., Synchron Team Up for European Customer Solutions

  5/6/2008